Fused heterocyclic compounds
The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1′): wherein, Ring A′ represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1′ represents (1) wherein, R 1a′ represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B2 represents a bond, —S—, -0-, —CO—, an optionally substituted methylene group, or —NR a′ — (R a′ represents a hydrogen atom, or an optionally substituted C 1-6 alkyl group), and Ring B 1′ represents an optionally further substituted 6- to 10-membered aromatic hydrocarbon ring, or an optionally further substituted 5- to 10-membered aromatic heterocyclic ring, or alternatively, L′ and R 1a′ may be taken together to form an optionally substituted bicyclic or tricyclic fused heterocyclic group, or (2), wherein, R 1b′ represents an optionally substituted phenyl group, or an optionally substituted 5- to 10-membered heterocyclic group, Ring B 2′ represents an optionally substituted benzene ring, an optionally substituted pyridine ring, an optionally substituted pyrimidine ring, an optionally substituted pyrazine ring, or an optionally substituted pyridazine ring, Ring D′ represents an optionally further substituted 5- or 6-membered ring, R 2′ represents a hydrogen atom, or a substituent, X′ represents ═N— or ═CR b′ —(R b′ represents a hydrogen atom, or a substituent), - - - - - represents that R b′ and R 2′ may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when.X′ is ═CR b′ , or a salt thereof.
1. A compound represented by the formula (1′):
wherein,
Ring A′ represents (1) an optionally substituted pyridine ring wherein the 4-position is unsubstituted, (2) an optionally substituted pyridazine ring, (3) an unsubstituted pyrimidine ring, or (4) an unsubstituted pyrazine ring,
R 1′ represents a group represented by
wherein,
R 1a′ represents a 5- to 10-membered heterocyclic group which may be substituted by 1 to 3 substituents selected from a group consisting of
(1) a C 1-6 alkyl group which may be substituted by 1-3 substituents selected from the group consisting of (a) a 2-(trimethylsilyl)ethoxy group, (b) a hydroxy group, (c) a C 1-6 alkoxy group and (d) a halogen atom;
(2) a halogen atom; and
(3) a cyano group,
L′ represents bond, —O—, —CO— or —NH, and
Ring B 1′ represents
(1) a benzene ring which may be substituted by a halogen atom,
(2) an unsubstituted pyridine ring,
(3) a dihydropyridine ring which may be substituted by an oxo group, or
(4) an unsubstituted pyrazole ring, or
alternatively, L′ and R 1a′ may be taken together to form
R 2′ represents a hydrogen atom, or a substituent,
X′ represents ═N— or ═CR b′— (R b′ represents a hydrogen atom, or a substituent),
- - - - - represents that R b′ and R 2′ may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when X′ is ═CR b′ —,
provided that:
5-ethoxy-3-[3-(morpholin-4-ylcarbonyl)phenyl]-1H-pyrazolo[4,3-b]pyridine
is excluded;
or a salt thereof.
2. A compound represented by the formula (1):
wherein,
Ring A represents an optionally substituted pyridine ring wherein the 4-position is unsubstituted,
R 1 represents a group represented by
wherein,
R 1a represents a 5- to 10-membered heterocyclic group which may be substituted by 1 to 3 substituents selected from a group consisting of
(1) a C 1-6 alkyl group which may be substituted by 1-3 substituents selected from the group consisting of (a) a 2-(trimethylsilyl)ethoxy group, (b) a hydroxy group, (c) a C 1-6 alkoxy group and (d) a halogen atom;
(2) a halogen atom; and
(3) a cyano group,
L represents bond, —O—, —CO— or —NH, and
Ring B 1 represents
(1) a benzene ring which may be substituted by a halogen atom,
(2) an unsubstituted pyridine ring,
(3) a dihydropyridine ring which may be substituted by an oxo group, or
(4) an unsubstituted pyrazole ring, or
alternatively, L′ and R 1a may be taken together to form
R 2 represents a hydrogen atom, or a substituent,
X represents ═N— or ═CR b — (R b represents a hydrogen atom, or a substituent),
- - - - - represents that R b and R 2 may form, taken together with the carbon atom and the nitrogen atom to which they are each adjacent, an optionally substituted 5- to 7-membered ring when X is ═CR b —,
provided that
5-ethoxy-3-[3-(morpholin-4-ylcarbonyl)phenyl]-1H-pyrazolo[4,3-b]pyridine
is excluded;
or a salt thereof.
3. The compound according to claim 2 , wherein Ring A is a pyridine ring wherein the 4-position is unsubstituted, and the other positions may be substituted by substituent(s) selected from the group consisting of (i) an optionally substituted C 1-6 alkyl group, (ii) an optionally substituted C 1-6 alkoxy group, (iii) a halogen atom and (iv) a cyano group, or a salt thereof.
4. The compound according to claim 2 , wherein Ring A is a pyridine ring wherein the 4-position is unsubstituted, and the other positions may be substituted by a halogen atom, or a salt thereof.
5. The compound according to claim 2 , or a salt thereof, wherein R 2 is an optionally substituted C 1-6 alkyl group.
6. The compound according to claim 2 , wherein L is —O—, or a salt thereof.
7. 1-(2,2-Difluoroethyl)-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1H-pyrazolo[4,3-b]pyridine, or a salt thereof.
8. 6-Fluoro-1-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1H-pyrazolo[4,3-b]pyridine, or a salt thereof.
9. 1-Ethyl-6-fluoro-3-(4-{[3-(2-methoxyethyl)-3H-imidazo[4,5-b]pyridin-2-yl]oxy}phenyl)-1H-pyrazolo[4,3-b]pyridine, or a salt thereof.
10. A medicament comprising the compound according to claim 1 or 2 , or a salt thereof.
11. The medicament according to claim 10 which is an agent for inhibiting phosphodiesterase 10A.